122 related articles for article (PubMed ID: 10708928)
1. Do we need better prognostic factors in node-negative breast cancer? Pro:
Thomssen C; Jänicke F
Eur J Cancer; 2000 Feb; 36(3):293-8. PubMed ID: 10708928
[No Abstract] [Full Text] [Related]
2. Minimal prognostic significance of sentinel lymph node metastasis in patients with cT1-2 and cN0 breast cancer.
Shigematsu H; Nishina M; Yasui D; Hirata T; Ozaki S
World J Surg Oncol; 2019 Feb; 17(1):41. PubMed ID: 30797231
[TBL] [Abstract][Full Text] [Related]
3. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
[TBL] [Abstract][Full Text] [Related]
4. Do we need better prognostic factors in nodal-negative breast cancer? Contra.
Kaufmann M; Scharl A
Eur J Cancer; 2000 Feb; 36(3):298-301. PubMed ID: 10708929
[No Abstract] [Full Text] [Related]
5. Do we need prognostic factors in nodal-negative breast cancer? Arbiter.
Hayes DF
Eur J Cancer; 2000 Feb; 36(3):302-6. PubMed ID: 10708930
[No Abstract] [Full Text] [Related]
6. Small tumor size and node-negative HER2-positive breast cancer: a step forward for a better treatment?
Crivellari D; Molino A
J Clin Oncol; 2010 Jun; 28(16):e257; author reply e258-9. PubMed ID: 20368536
[No Abstract] [Full Text] [Related]
7. Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.
Yamashita H; Ogiya A; Shien T; Horimoto Y; Masuda N; Inao T; Osako T; Takahashi M; Endo Y; Hosoda M; Ishida N; Horii R; Yamazaki K; Miyoshi Y; Yasojima H; Tomioka N;
Breast Cancer; 2016 Nov; 23(6):830-843. PubMed ID: 26467036
[TBL] [Abstract][Full Text] [Related]
8. The lymph node ratio as an independent prognostic factor for non-metastatic node-positive breast cancer recurrence and mortality.
Solak M; Turkoz FP; Keskin O; Aksoy S; Babacan T; Sarici F; Kertmen N; Sever AR; Altundag K
J BUON; 2015; 20(3):737-45. PubMed ID: 26214625
[TBL] [Abstract][Full Text] [Related]
9. [Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].
Li Q; Xu BH; Zhang P; Li Q; Yuan P; Wang JY; Luo Y; Ma F; Fan Y; Li Q
Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):207-11. PubMed ID: 23880002
[TBL] [Abstract][Full Text] [Related]
10. [Immunohistologic tumor cell detection in lymph nodes in node negative breast cancer: correlation with "established" and "recent" prognostic factors].
Gerber B; Krause A; Kimmig R
Gynakol Geburtshilfliche Rundsch; 1995; 35 Suppl 1():32-5. PubMed ID: 8672923
[TBL] [Abstract][Full Text] [Related]
11. Survival benefit of post-mastectomy radiotherapy in breast carcinoma patients with T1-2 tumor and 1-3 axillary lymph node(s) metastasis.
Duraker N; Demir D; Bati B; Yilmaz BD; Bati Y; Çaynak ZC; Sobutay E
Jpn J Clin Oncol; 2012 Jul; 42(7):601-8. PubMed ID: 22511807
[TBL] [Abstract][Full Text] [Related]
12. Use of sentinel node biopsy expands.
Peres J
J Natl Cancer Inst; 2013 Oct; 105(19):1423-4. PubMed ID: 24052620
[No Abstract] [Full Text] [Related]
13. What to do about occult metastases in breast cancer? Standards shift, but doubts linger.
Schmidt C
J Natl Cancer Inst; 2011 May; 103(10):784-5. PubMed ID: 21551415
[No Abstract] [Full Text] [Related]
14. [Clinical characteristics and prognostic factors of female breast cancer patients with 10 or more positive lymph nodes: a report of 128 patients].
Guan Y; Xu BH; Li Q; Zhang P; Zhao LM; Yuan P; Wang JY
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(2):77-81. PubMed ID: 18353207
[TBL] [Abstract][Full Text] [Related]
15. [The effect of axillary lymph node status on the prognosis of patients with local-regional recurrence after breast-conserving surgery].
Zhang Z; Zhang W; Li ZJ; Wang XM; Cao XC; Xiao CH
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):347-351. PubMed ID: 29860761
[No Abstract] [Full Text] [Related]
16. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.
Jänicke F; Prechtl A; Thomssen C; Harbeck N; Meisner C; Untch M; Sweep CG; Selbmann HK; Graeff H; Schmitt M;
J Natl Cancer Inst; 2001 Jun; 93(12):913-20. PubMed ID: 11416112
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors of young women (≤ 35 years) with node positive breast cancer: possible influence on post-therapeutic follow-up.
Filleron T; Md FD; Kramar A; Spielmann M; Levy C; Fumoleau P; Canon JL; Martin AL; Roché H
Bull Cancer; 2013; 100(7-8):22-9. PubMed ID: 23822935
[TBL] [Abstract][Full Text] [Related]
18. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years.
Reed W; Hannisdal E; Boehler PJ; Gundersen S; Host H; Marthin J
Cancer; 2000 Feb; 88(4):804-13. PubMed ID: 10679650
[TBL] [Abstract][Full Text] [Related]
19. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
[TBL] [Abstract][Full Text] [Related]
20. The prognostic significance of nodal ratio on breast cancer recurrence and its potential for incorporation in a new prognostic index.
Martin FT; O'Fearraigh C; Hanley C; Curran C; Sweeney KJ; Kerin MJ
Breast J; 2013; 19(4):388-93. PubMed ID: 23721403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
